🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Clene Inc (NAS:CLNN)
News
Clene Inc
NAS
:CLNN (USA) Â
Ordinary Shares
$ 0.35
+0.0095 (+2.82%)
10:09 PM EST
P/E:
At Loss
P/B:
3.47
Market Cap:
$ 44.50M
Enterprise V:
$ 40.44M
Volume:
366.18K
Avg Vol (2M):
1.06M
Warning! GuruFocus detected 8 Severe warning signs with CLNN.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
366.18K
Market Cap $:
44.50M
PE Ratio:
At Loss
Avg Vol (2M):
1.06M
Enterprise Value $:
40.44M
PB Ratio:
3.47
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Clene Inc (NAS:CLNN) Stock News, Headlines & Updates
Clene Inc Stock News from GuruFocus
Total 62
1
2
Apr 16, 2024
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Marketwired
•
4:00pm
Feb 06, 2024
Clene Inc. at Cantor Fitzgerald Global Healthcare Conference Transcript
GuruFocus Research
•
9:23am
Clene Inc. at Canaccord Genuity Growth Conference Transcript
GuruFocus Research
•
9:23am
Clene Inc. at ROTH Conference Transcript
GuruFocus Research
•
9:23am
Clene Inc. To Discuss Healey ALS Platform Trial Data Update Call Transcript
GuruFocus Research
•
9:23am
Clene Inc. To Discuss CNM-Au8 Topline Data From The HEALEY ALS Platform Trial Call Transcript
GuruFocus Research
•
9:23am
Clene Inc. Annual Shareholders Meeting Transcript
GuruFocus Research
•
9:23am
Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results Transcript
GuruFocus Research
•
9:23am
Nov 07, 2023
Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45.1M NINDS Grant Highlighted
GuruFocus Research
•
7:57am
Oct 05, 2023
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Marketwired
•
9:00am
Sep 28, 2023
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Marketwired
•
7:00am
Sep 25, 2023
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
Marketwired
•
3:00pm
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Marketwired
•
6:00am
Aug 30, 2023
Clene to Present at Upcoming September Conferences
Marketwired
•
8:00am
Aug 29, 2023
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
Marketwired
•
6:00am
Aug 14, 2023
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Marketwired
•
7:00am
Aug 02, 2023
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
Marketwired
•
6:00am
Jun 26, 2023
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine
Marketwired
•
7:00am
Jun 21, 2023
Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
Marketwired
•
11:00am
Feb 27, 2023
Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System
sperokesalga
•
6:00am
Feb 13, 2023
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
sperokesalga
•
7:00am
Jan 11, 2023
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
Stock market mentor
•
7:00am
Dec 27, 2022
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
Tiesvg
•
4:00pm
Nov 28, 2022
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
Value_Insider
•
7:00am
Oct 31, 2022
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Value_Insider
•
7:00am
Aug 30, 2022
Clene to Present at Upcoming September Investor Conferences
Ds***
•
6:00am
Aug 15, 2022
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
PurpleRose
•
7:00am
Aug 12, 2022
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
PurpleRose
•
4:00pm
Jul 19, 2022
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
PurpleRose
•
6:00am
Jul 14, 2022
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
PurpleRose
•
6:42am
Jul 12, 2022
Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
PurpleRose
•
7:20am
Jul 02, 2022
Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
GuruFocusNews
•
7:19am
Jul 01, 2022
New Data from Clene's RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
GuruFocusNews
•
6:18am
Jun 27, 2022
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
GuruFocusNews
•
6:27am
Jun 12, 2022
Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
GuruFocusNews
•
6:17am
Jun 11, 2022
New Data from Clene's RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
GuruFocusNews
•
6:15am
Jun 02, 2022
Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
GuruFocusNews
•
6:15am
Jun 01, 2022
New Data from Clene's RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
GuruFocusNews
•
6:14am
May 16, 2022
Clene to Present at Upcoming Investor Conferences
GuruFocusNews
•
7:31am
Apr 01, 2022
Updated Interim Data from Clene Nanomedicine's RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
GuruFocusNews
•
6:00am
Total 62
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news